SERIES C·Nov 17, 2026, 10:27 PM ET
Isomorphic Labs secures $5B to prepare drug programs for human testing
TL;DR:
- Isomorphic Labs secured $5 billion six months after its $2.1 billion Series B.
- Greenoaks and Sequoia Capital jointly led the financing, while Alphabet and all existing investors participated.
- Isomorphic Labs will invest in IsoDDE and the infrastructure needed to move drug programs toward human trials.
Summary
Isomorphic Labs secured a $5 billion Series C, with Greenoaks and Sequoia Capital sharing the lead. Alphabet, its parent, invested alongside returning and new backers. The money supports its IsoDDE drug-design engine, preclinical candidates and preparations for clinical development. That puts the focus on progressing computer-designed medicines toward testing in people, rather than model development alone.